Cargando…

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Relecom, Allan, Federico, Massimo, Connors, Joseph M., Coiffier, Bertrand, Biasoli, Irene, Moccia, Alden, Salles, Gilles, McKee, Thomas, Miralbell, Raymond, Borchmann, Peter, Kuruvilla, John, Johnson, Peter, Cavalli, Franco, Delavy, Martine, Dietrich, Pierre-Yves, Flahault, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084688/ https://www.ncbi.nlm.nih.gov/pubmed/32182952 http://dx.doi.org/10.3390/ijerph17051783

Ejemplares similares

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial
por: Oertel, Michael, et al.
Publicado: (2023)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron D., et al.
Publicado: (2021)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

Fertility in female survivors of Hodgkin's lymphoma
por: Biasoli, Irene, et al.
Publicado: (2012)

P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
por: Stadtbaeumer, Nele, et al.
Publicado: (2022)

The outcome of older adults with classic Hodgkin lymphoma in British Columbia
por: Cheng, Phoebe T. M., et al.
Publicado: (2022)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
por: Warzocha, K., et al.
Publicado: (1998)

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma
por: Benckendorff, Julian, et al.
Publicado: (2021)

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
por: Pettengell, Ruth, et al.
Publicado: (2018)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
por: Borchmann, Sven, et al.
Publicado: (2018)

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT
por: Rossi, Cédric, et al.
Publicado: (2017)

Classical Hodgkin Lymphoma Presenting with Severe, Recurrent Hypothermic Episodes
por: Hansen, Jonas Juul, et al.
Publicado: (2018)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
por: Borchmann, Sven, et al.
Publicado: (2017)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
por: Momotow, Jesko, et al.
Publicado: (2019)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Suicide in European Hodgkin Lymphoma Patients
por: Kim, Austin I., et al.
Publicado: (2019)

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7pgip6dauj7d28dogdn7com1ao